MDxHealth is a commercial-stage precision diagnostics company focused on the prostate cancer diagnostic pathway. The company develops and sells molecular diagnostic tests that help urologists and patients make decisions at key points in the prostate cancer journey. Its core test menu covers three stages: pre-biopsy risk stratification (Exo mdx, a urine-based test acquired from Exosome Diagnostics in 2025), post-negative-biopsy guidance (Confirm mdx, a tissue-based epigenetic test), and post-diagnosis treatment selection (GPS mdx, a tissue-based genomic test acquired from Exact Sciences in 2022). MDxHealth also sells Resolve mdx, a PCR-based urine test for UTIs. Customers are primarily community-based urologists and large urology group practices in the U.S., served by a direct sales force of roughly 60 reps. MDxHealth operates as a lab services company — physicians order tests, MDxHealth processes them in its own CLIA-certified labs, and revenue is collected through Medicare and commercial insurance reimbursement. Tissue-based tests (Confirm mdx and GPS mdx) carry Medicare reimbursement rates of approximately $2,000 and $3,850, respectively, and account for roughly three-quarters of revenue. MDxHealth's growth levers are sales force productivity, deeper penetration within existing urology practices, reimbursement expansion, and bolt-on M&A to extend the test menu — with bladder cancer cited as a potential adjacent market.